



Catalogue no. 82-225-XIE — No. 003

ISSN: 1715-2100

ISBN: 0-662-41802-6

## Canadian Cancer Registry Manuals

# Guidelines for Abstracting and Determining Death Certificate only (DCO) Cases for Provincial/Territorial Cancer Registries (PTCRs) in Canada

by Michel Cormier

Health Statistics Division  
Client Custom Services  
Room 2200, Main Building, Ottawa, K1A 0T6

Telephone: 1 613 951-1746



Statistics  
Canada

Statistique  
Canada

Canada

# Canadian Cancer Registry Manuals

## Guidelines for Abstracting and Determining Death Certificate only (DCO) Cases for Provincial/Territorial Cancer Registries (PTCRs) in Canada

by

Michel Cormier

**82-225-XIE No. 003**  
**ISSN: 1715-2100**  
**ISBN: 0-662-41802-6**

**Health Statistics Division**  
**Room 2200, Main Building, Ottawa, K1A 0T6**

**How to obtain more information :**  
Client Custom Services Unit: 1 613 951-1746  
E-Mail: [HD-DS@statcan.ca](mailto:HD-DS@statcan.ca)

**October 2005**

Published by authority of the Minister responsible for Statistics Canada

© Minister of Industry, 2005

All rights reserved. The content of this publication may be reproduced, in whole or in part, and by any means, without further permission from Statistics Canada, subject to the following conditions: that it is done solely for the purposes of private study, research, criticism, review, newspaper summary, and/or for non-commercial purposes; and that Statistics Canada be fully acknowledged as follows: Source (or "Adapted from", if appropriate): Statistics Canada, name of product, catalogue, volume and issue numbers, reference period and page(s). Otherwise, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopy, for any purposes, without the prior written permission of Licensing Services, Marketing Division, Statistics Canada, Ottawa, Ontario, Canada K1A 0T6

*La version française de cette publication est disponible sur demande (n° 82-225-XIF au catalogue).*

## Table of contents

	Page
<b>Preface</b> .....	4
<b>Guidelines</b> .....	4
1. Definitions.....	6
2. Process .....	6
Appendix A (cover letter to institution).....	9
Appendix B (cover letter to informant) .....	10
Appendix C – Purpose: compare the DCN to the PTCR before followback for determining ‘like’ tumours based on Vital Statistics Data .....	11

## **Preface**

The Committee on Data and Quality Management (DQMC) have expanded the Guidelines for Abstracting and Determining DCO Cases for PTCRs in Canada that was approved and distributed in 2002. Appendix C provides guidelines for determining like tumours when processing Death Certificate Notifications (DCNs).

The intent is for each PTCR to incorporate these guidelines into the Death Clearance Process within their facility. Reference this amendment when performing a comparison between the Death Certificate Notification and the Registry database prior to following back with external facilities for clarification.

The goal is to standardize the death clearance process while decreasing resources used for follow back when determining a new versus recurrent primary tumour.

If a Death Certificate Notification (DCN) is reported with a cancer cause of death that is not found in the registry, the case should be followed back to determine if it meets the criteria for cancer registration. Follow back is the process of actively searching for additional information on DCNs at the patient and disease level and updating the cancer database as a complete abstract when possible. Processing is required when the decedent was a resident of your province/territory at the time of death, and a reportable cancer is mentioned on the DCN but no record is found in the PTCR database.

## **Guidelines**

Cancer registries have identified access to death information as a critical component for operating a high quality program. There are two main reasons for acquiring this particular data, including:

1. **Determination of Death Status for Currently Enrolled Cases:** Once a registry has enrolled a case of cancer the addition of death information can provide a more complete picture of how cancer has impacted this individual. Death information on a specific case can remove it from active follow up routines and allow registries to perform more accurate and complete survival calculations.
2. **Case Completeness:** To ensure a high level of case completeness a registry typically relies on a variety of methods to ascertain newly diagnosed cancers. One common method is to complete a linkage to vital statistics information regarding cause(s) of death. If an individual is reported with a cancer cause of death and is not found in the registry the case should be followed back to determine if it meets the criteria for cancer registration.

Therefore it is important that PTCRs enter into agreements with Vital Statistics registrars to receive at a minimum **all** cases for which cancer is listed on any part of the medical certificate of death. In Canada death registration is subject to provincial mandates and includes the completion of a Statement of Death and/or a Medical Certificate of Death. Cancer registries receive death notifications in various formats i.e., hardcopy, electronically, or computer files and at varying intervals i.e., monthly, quarterly or annually.

The ideal is to receive notification of all deaths including all causes of death occurring within the province, enabling the registry to perform a comprehensive death clearance. When linked with the registry database this information will result in both matched and non-matched cancer incidence. A

death certificate with a reportable tumour listed that does not link to other records in the cancer registry is called a Death Certificate Notification (DCN) and requires further investigation. DCNs include cases in which the underlying cause of death is cancer as well as cases in which cancer is simply mentioned on the death certificate. When additional information is obtained the case should be registered with that year's incidence data. If additional information cannot be obtained, the case is a true Death Certificate Only (DCO) and can be reported as such to the Canadian Cancer Registry (CCR).

Death certificate information is a critical component in the registry certification process operated by the North American Association of Central Cancer Registries (NAACCR). To be eligible for NAACCR certification a PTCR must participate in the NAACCR Call for Data. The data criteria reviewed during this process include: Completeness, passing EDITS, DCO, Interval for Criteria, Timeliness, Duplicate Reports and Missing Data Fields in Sex, Age, County and Race. The DCO certification requirement is less than 5% silver and less than 3% gold.

The CCR and NAACCR accepted formula for calculating the DCO rate is:

$$\left[ \frac{\text{\# of true DCOs for the year}}{\text{total \# of cancer cases for the year}} \right] \times 100 = \text{DCO rate}$$

***Differences exist in the denominator as CCR does not include in situ bladder cancers and NAACCR does. Where cancer cases = all unduplicated invasive cancers + in situ bladder cancers within the diagnosis year for state (provincial) residents. These include all cases identified and abstracted from the death clearance project and all true DCOs. This information is included in the NAACCR Call for Data.***  
(Source: NAACCR Series II: Calculating the DCO Rate)

## 1. Definitions

### **Cause of death**

The causes of death to be entered on the medical certificate of cause of death are all those diseases; morbid conditions or injuries which either resulted in or contributed to death and the circumstances of the accident or violence which produced any such injuries.

(Source: World Health Assembly, Article 23 of the Constitution of the World Health Organization. ICD-9 pg. 763)

### **Death certificate notification (DCN)**

Death certificate notification is a cancer death identified from any source including a Vital Statistics Death Registration that could not be linked (electronically or manually) to an existing cancer record.

### **Death certificate only (DCO)**

“Death certificate only” means that the only source of information about the case was a death certificate. This category includes deaths where either the Underlying Cause of Death is cancer, or there is any mention of cancer on the death certificate.

(Source: CCR – Report No. 3.2.2. – Input Data Dictionary, page 79. Revised on: 17/06/94.)

As of January 1, 2000 mortality information in Canada was captured by Vital Statistics using the ICD-10 classification system.

### **Follow back (FB)**

Follow back is the process of actively searching for additional information on DCNs at the patient and disease level and updating the cancer database as a complete abstract when possible. If additional information cannot be found the case is a true DCO.

### **Underlying cause of death**

The underlying cause of death is (a) the disease or injury which initiated the train of events leading directly to death, or (b) the circumstances of the accident or violence which produced the fatal injury.

(Source: World Health Assembly, Article 23 of the Constitution of the World Health Organization. ICD-9 pg. 763)

## 2. Process

The process for determining a DCO case will vary and should be modified to meet the requirements of the individual PTCRs. PTCRs should match DCNs to their database; those cancer deaths that do not match require further investigation. Processing is required when the decedent was a resident of your province at the time of death, and a reportable cancer is mentioned on the DCN and no record is found in the PTCR database. No further processing is required when the only tumour mentioned on the DCN is a non-reportable tumour, the decedent was a non-resident of your province (forward to province of ownership if agreements are in place) or when a non-cancer death is identified.

The underlying cause of death field is intended to capture a patient’s official cause of death. As this variable is important for record linkage purposes and has legal implications, the death information coded and provided to cancer registries from provincial and territorial Vital Statistics offices should not be altered even when cancer registries have more complete or detailed diagnostic information. The only PTCR reported data that may be changed on the CCR patient record because of a confirmation of death are: Date of Death, Province/Country of Death and

### Death Registration Number.

(Source, CCR – Report No. 3.2.1 – Coding and Reporting Guidelines – December 18, 1995)

#### A. DCN Match to Provincial/Territorial cancer registry database. (Example: positive match on four variables i.e., HIN, Surname, Sex and DOB).

- Determine same primary versus new primary.
- Identify discrepancies between cancer on certificate of death and registry diagnosis codes. Update missing or incomplete fields.

An inconclusive Match shows some discrepancies between identifiers in the incidence and death data but the records may belong to the same person. (Example: positive or close match on the four variables i.e., HIN positive match, mismatch with surname, sex or DOB.

- Visual verification to determine if it's "close enough" to be judged a match or non-match.
- FB to make a valid determination.

Followback (FB) for new primaries or abstract for additional DCO primaries. Edit and review cases in registry database not microscopically confirmed.

#### B. DCN cancer death, Non-match to Provincial/Territorial cancer registry database.

Nonmatched cancer deaths are cleared in a variety of ways, depending on the PTCR's ability to staff a DCO clearance program. Each non-match cancer death must be manually reviewed for reportability and to ascertain where to follow back. Followback sources include facility (chronic care, hospital/nursing home), coroner and attending physician where the death occurred.

Based upon the information received from follow back, the case may be abstracted as a DCO.

- Follow Back is recommended by form letter to the institution (Appendix A) where the patient expired and secondly to the informant (Appendix B) who signed the death certificate to obtain additional information.
- Cases that are identified after followback should be added to the appropriate diagnosis year as actual incident records (not DCOs).
- Cases where no additional information is obtained should be reported to the CCR as a DCO.

#### C. Standard conventions for abstracting DCO cases:

1. If FB is not returned from facility/physician, the information from the DCN may be used and the case considered a DCO.
2. If a date of diagnosis or an approximate date cannot be established, the case is a DCO and the date of death is used as the date of diagnosis.
3. Follow standard coding conventions for site/histology.
4. There may be more than one primary noted on the Death Certificate. More than one DCO abstract may be required.
5. Code the histology from the Death Certificate, i.e., squamous cell carcinoma, adenocarcinoma, etc., if available. If "carcinoma" is recorded, code as 8010/3. If "cancer" is recorded, code as 8000/3.
6. Code the Primary Site recorded on the Death Certificate, i.e., lung, prostate, breast.
7. Melanoma, unknown primary site code to Malignant melanoma of skin, site unspecified (ICD-9 172.9, ICD-10 C43.9).

8. Lymphoma, unknown primary site code to Lymph Nodes, NOS (ICD-9 202.8, ICD-10 C85.9).
9. Leukemia is always coded to Bone Marrow (ICD-9 208.9, ICD-10 C95.9).
10. Watch for primary sites where metastases are common (Lung, Liver, Brain and Bone).
11. The death certificate may state “metastatic liver cancer” or “metastatic bone cancer”. If it is unclear if the site recorded is the primary or a metastatic site, code to Unknown Primary Site (ICD-9 199.0, ICD-10 C80.9).
12. Stage is always “unknown”.
13. Diagnostic confirmation is always “unknown”.
14. No treatment is recorded, even if noted on the DCN.
15. Include DCO cases in edits.



## Appendix A

(Cover letter to Institution)

PTCR

Inside address

To Whom It May Concern:

The Registry Name is presently completing the Death Certificate Only (DCO) follow back process for year/s. DCO means that the only source of information about the case was a death certificate. The death certificate identified the decedent as having expired in your facility however the cancer registry has no prior information on this case through its routine data collection. Data collection is legislated by act/privacy act. Enclosed you will find a Registry Form letter for completion, it is important that we collect the initial date and address at time of diagnosis. If, your records do not identify this patient as having cancer please indicate and we will adjust our records accordingly.

By completing the enclosed Registry Form letter we can finalize the information on this patient. Complete information permits the calculation of survival rates on patients diagnosed with cancer, facilitates epidemiological studies and improves the completeness and quality of reported death and other demographic information. Your continued support in improving the quality of data allows us to participate in provincial and national studies and to provide accurate statistics on an ongoing basis to our stakeholders.

If there are any questions or concerns, please do not hesitate to contact me, contact name at facility name and phone number.

Sincerely yours,

Signature

Enclosure

## Appendix B

(Cover letter to Informant)

PTCR

Inside address

Dear Insert name here,

The Registry Name is presently completing the Death Certificate Only (DCO) follow back process for year/s. DCO means that the only source of information about the case was a death certificate. The death certificate stated the decedent had cancer, however the cancer registry has no prior information on this case through its routine data collection. Data collection is legislated by act/privacy act. The death certificate identifies you as the last attending physician at time of death for patient name. Enclosed you will find a Registry Form letter for completion, it is important that we collect the initial date and address at time of diagnosis. If, your records do not identify this patient as having cancer please indicate and we will adjust our records accordingly.

By completing the enclosed Registry Form letter we can finalize the information on this patient. Complete information permits the calculation of survival rates on patients diagnosed with cancer, facilitates epidemiological studies and improves the completeness and quality of reported death and other demographic information. Your continued support in improving the quality of data allows us to participate in provincial and national studies and to provide accurate statistics on an ongoing basis to our stakeholders.

If there are any questions or concerns, please do not hesitate to contact me, contact name at facility name and phone number.

Sincerely yours,

Signature

Enclosure

## Appendix C

Purpose: Compare the DCN to the PTCR before followback for determining 'like' tumours based on Vital Statistics Data					
Method: If the ICD-10 Code based on the DCN is the same or within the range of the ICD-O-T code or ICD-O-M code from the PTCR, consider this the same tumour.					
Specific ICD-10	Description	Related to ICD-O-T	Description	Related to ICD-O-M	Description
<b>C00-C14</b>	<b>Malignant neoplasm of Lip, Oral Cavity and Pharynx</b>		<b>Lip, Oral Cavity and Pharynx</b>		
C00	C00 Malignant neoplasm of Lip (excludes skin of lip C44.0)	C00	C00 Lip (excludes skin of lip C44.0)		
C01-C06	C01 Malignant neoplasm of Lip Base of tongue, C02 Other and Unspecified Parts of tongue, C03 Gum, C04 Floor of Mouth, C05 Palate, C06 Other and unspec. Parts of mouth	C01-C06	C01 Base of tongue, C02 Other and Unspecified Parts of tongue, C03 Gum, C04 Floor of Mouth, C05 Palate, C06 Other and unspec. Parts of mouth		
C07	C07 Malignant neoplasm of Parotid Gland	C07, C08, C14	C07 Parotid Gland, C08 Other and unspec. Major salivary glands, C14 Other and ill-defined sites in lip, oral cavity and pharynx		
C08	C08 Malignant neoplasm of Other and unspec. Major salivary glands	C07, C08, C14	C07 Parotid Gland, C08 Other and unspec. Major salivary glands, C14 Other and ill-defined sites in lip, oral cavity and pharynx		
C09	C09 Malignant neoplasm of Tonsil	C09, C10, C14	C09 Tonsil, C10 Oropharynx, C14 Other and ill-defined sites in lip, oral cavity and pharynx		
C10-C13	C10 Malignant neoplasm of Oropharynx, C11 Nasopharynx, C12 Pyriform sinus, C13 Hypopharynx	C09-C14	C09 Tonsil, C10 Oropharynx, C11 Nasopharynx, C12 Pyriform sinus, C13 Hypopharynx, C14 Other and ill-defined sites in lip, oral cavity and pharynx		
C14	C14 Malignant neoplasm of Other and ill-defined sites in lip, oral cavity and pharynx	C00-C14	Lip, oral cavity and pharynx		

Appendix C

C15-C26	C15-C26 Malignant neoplasm of Digestive Organs		Digestive Organs		
C15	C15 Malignant neoplasm of Esophagus	C15, C16, C26, C48	C15 Esophagus, C16 Stomach, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C16	C16 Malignant neoplasm of Stomach,	C15-C17, C26, C48	C15 Esophagus, C16 Stomach, C17 Small Intestine, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C17	C17 Malignant neoplasm of Small Intestine	C16-C18,C26, C48	C16 Stomach, C17 Small Intestine, C18 Colon, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C18	C18 Malignant neoplasm of Colon	C17 – C21, C26, C48	C17 Small Intestine, C18 Colon, C19 Rectosigmoid Junction, C20 Rectum, C21 Anus and Anal Canal, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C19	C19 Malignant neoplasm of Recotsigmoid Junction	C18-C21,C26, C48	C18 Colon, C19 Recotsigmoid Junction, C20 Rectum, C21 Anus and Anal Canal, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C20	C20 Malignant neoplasm of Rectum	C19-C21,C26, C48	C19 Recotsigmoid Junction, C20 Rectum, C21 Anus and Anal Canal, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C21	C21 Malignant neoplasm of Anus and Anal Canal	C19-C21,C26,C48	C19 Recotsigmoid Junction, C20 Rectum, C21 Anus and Anal Canal, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C22	C22 Malignant neoplasm of liver		Any site. Assume to be metastatic as 90% of liver cancers are.		
C23	C23 Malignant neoplasm of Gallbladder	C23, C24, C26, C48	C23 Gallbladder, C24 Other and Unspec parts of biliary tract, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C24	C24 Malignant neoplasm of Other and Unspec parts of biliary tract	C22-C24,C26, C48	C22 Liver and Intrahepatic bile ducts, C23 Gallbladder, C24 Other and Unspec parts of biliary tract, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C25	C25 Malignant neoplasm of Pancreas	C26	C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		
C26	C26 Malignant neoplasm of Other and ill-defined digestive organs, Other and ill-defined digestive organs	C15-C26, C48	C15 Esophagus, C16 Stomach, C17 Small Intestine, C18 Colon, C19 Recotsigmoid Junction, C20 Rectum, C21 Anus and Anal Canal, C22 Liver and Intrahepatic bile ducts, C23 Gallbladder, C24 Other and Unspec parts of biliary tract, C25 Pancreas, C26 Other and ill-defined digestive organs, C48 Retroperitoneum, Peritoneum		

Appendix C

C30-C39	Malignant neoplasms of Respiratory and Intrathoracic Organs		Respiratory and Intrathoracic Organs		
C30	C30 Malignant neoplasm of Nasal cavity and middle ear	C30, C31, C39	C30 Nasal cavity and middle ear, C31 Accessory Sinus, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
C31	C31 Malignant neoplasm of Accessory sinus,	C30, C31, C39	C30 Malignant Neoplasm Nasal Cavity and Middle Ear, C31 Accessory sinus, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
C32	C32 Malignant neoplasm of Larynx	C32, C39	C32 Larynx, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
C33	C33 Malignant neoplasm of Trachea	C33-C39	C33 Trachea, C34 Bronchus and lung, C37 Thymus, C38 Heart, Mediastinum and Pleura, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
C34	C34 Malignant neoplasm of Bronchus and lung	C33-C39	C33 Trachea, C34 Bronchus and lung, C37 Thymus, C38 Heart, Mediastinum and Pleura, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
C37	C37 Malignant neoplasm of Thymus	C33-C39, C74	C33 Trachea, C34 Bronchus and lung, C37 Thymus, C38 Heart, Mediastinum and Pleura and C39 Other and ill-defined sites within respiratory system and intrathoracic organs.		
C38	C38 Malignant neoplasm of Heart, Mediastinum and Pleura	C33-C39, C74	C33 Trachea, C34 Bronchus and lung, C37 Thymus, C38 Heart, Mediastinum and Pleura and C39 Other and ill-defined sites within respiratory system and intrathoracic organs.		
C39	C39 Malignant neoplasm of Other and ill-defined sites within respiratory system and intrathoracic organs	C30-C39	C30 Nasal cavity and middle ear, C31 Accessory sinus, C32 Larynx, C33 Trachea, C34 Bronchus and lung, C37 Thymus, C38 Heart, Mediastinum and Pleura, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
C40-C41	Malignant neoplasm of Bones and Articular Cartilage		Bones and Articular Cartilage		
C40	C40 Malignant neoplasm of bone and articular cartilage of limbs	C40, C41, C49	C34 Bronchus and Lung, C40-C41 Bones Joints and Articular Cartilage, C49 Connective, subcutaneous and other soft tissues, C50 Breast, C61 Prostate, C64 Kidney and C73 Thyroid Gland		
C41	C41 Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C40, C41, C49	C34 Bronchus and Lung, C40-C41 Bones Joints and Articular Cartilage, C49 Connective, subcutaneous and other soft tissues, C50 Breast, C61 Prostate, C64 Kidney and C73 Thyroid Gland	8720-8790	872-879 Nevi and Melanomas
C43	C43 Malignant neoplasm of skin	C44, C69	C44 Skin, C69 Eye and Adnexa		
C44	C44 Other malignant neoplasms of skin	C44	C44 Skin, C69 Eye and Adnexa		
C47-C49	Malignant neoplasm of Mesothelial and Soft Tissue		Mesothelial and Soft Tissue		
C47	C47 Malignant neoplasm of Peripheral nerves and autonomic nervous system	C47, C49	C47 Peripheral nerves and autonomic nervous system, C49 Connective, subcutaneous and other soft tissues		
C48	C48 Malignant neoplasm of Retroperitoneum and peritoneum	C48, C49	C48 Retroperitoneum and peritoneum, C49 Connective, subcutaneous and other soft tissues		
C49	C49 Connective, subcutaneous and other soft tissues	C48-C49	C49 Connective, subcutaneous and other soft tissues		
C50	Malignant neoplasm of Breast	Breast			
C50	C50 Malignant neoplasm of Breast	C50	C50 Breast		

Appendix C

C51-C58	Malignant neoplasm of Female Genital Organs		Female Genital Organs		
C51	C51 Malignant neoplasm of Vulva	C51-C52, C57-C58	C51 Vulva, C52 Vagina, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C52	C52 Malignant neoplasm of Vagina	C51-C53, C57-C58	C51 Vulva, C52 Vagina, C53 Cervix uteri, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C53	C53 Malignant neoplasm of Cervix uteri	C52-C54, C57-C58	C52 Vagina, C53 Cervix uteri, C54 Corpus uteri, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C54	C54 Malignant neoplasm of Corpus uteri	C52-C55, C47-C58	C52 Vagina, C53 Cervix uteri, C54 Corpus uteri, C55 Uterus, nos, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C55	C55 Malignant neoplasm of Uterus, nos	C52-C55, C47-C58	C52 Vagina, C53 Cervix uteri, C54 Corpus uteri, C55 Uterus, nos, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C56	C56 Malignant neoplasm of Ovary	C51-C58	C55 Uterus, nos, C56 Ovary, C57 Other and Unspec. Female Genital Organs		
C57	C57 Malignant neoplasm of Other and Unspec. Female Genital Organs	C51-C58	C51 Vulva, C52 Vagina, C53 Cervix uteri, C54 Corpus uteri, C55 Uterus, nos, C56 Ovary, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C58	C58 Malignant neoplasm of Placenta	C51-C58	C54 Corpus uteri, C55 Uterus, nos, C57 Other and Unspec. Female Genital Organs, C58 Placenta		
C60-C63	Malignant neoplasm of Male Genital Organs		Male Genital Organs		
C60	C60 Malignant neoplasm of Penis,	C60, C62-C63	C60 Penis, C62 Testis, C63 Other and Unspec. Male Genital Organs		
C61	C61 Malignant neoplasm of Prostate	C60-C63	C60 Penis, C61 Prostate, C62 Testis, C63 Other and Unspec. Male Genital Organs		
C62	C62 Malignant neoplasm of Testis	C60, C62-C63	C60 Penis, C62 Testis, C63 Other and Unspec. Male Genital Organs		
C63	C63 Malignant neoplasm of Other and Unspec. Male Genital Organs	C60, C62-C63	C60 Penis, C61 Prostate, C62 Testis, C63 Other and Unspec. Male Genital Organs		
C64-C68	Urinary Tract				
C64	C64 Malignant neoplasm of Kidney	C64-C66, C68	C64 Kidney, C65 Renal Pelvis, C66 Ureter, C68 Other and Unspec. Urinary Organs		
C65	C65 Malignant neoplasm of Renal Pelvis	C64-C66, C68	C64 Kidney, C65 Renal Pelvis, C66 Ureter, C68 Other and Unspec. Urinary Organs		
C66	C66 Malignant neoplasm of Ureter	C64-C66, C68	C64 Kidney, C65 Renal Pelvis, C66 Ureter, C68 Other and Unspec. Urinary Organs		
C67	C67 Malignant neoplasm of Bladder	C64-C68	C64 Kidney, C65 Renal Pelvis, C66 Ureter, C67 Bladder, C68 Other and Unspec. Urinary Organs		
C68	C68 Malignant neoplasm of Other and Unspec. Urinary Organs	C64-C66, C68	C64 Kidney, C65 Renal Pelvis, C66 Ureter, C67 Bladder, C68 Other and Unspec. Urinary Organs		

Appendix C

C69-C72	Eye, Brain and other Central Nervous System				
C69 C70	C69 Malignant neoplasm of Eye and Adnexa C70 Malignant neoplasm of Meninges	C69 C70-C72, C751, C752	C69 Eye and Adnexa C70 Meninges, C71 Brain, C72 Spinal cord, Cranial nerves and other parts of the CNS. C75.1 Pituitary gland, C75.2 Craniopharyngeal duct		
C71	C71 Malignant neoplasm of Brain	C70-C72, C751, C752	C70 Meninges, C71 Brain, C72 Spinal cord, Cranial nerves and other parts of the CNS. C75.1 Pituitary gland, C75.2 Craniopharyngeal duct		
C72	C72 Malignant neoplasm of Spinal cord	C70-C72, C751, C752	C70 Meninges, C71 Brain, C72 Spinal cord, Cranial nerves and other parts of the CNS. C75.1 Pituitary gland, C75.2 Craniopharyngeal duct		
C73-C75	Thyroid and Endocrine Glands				
C73	C73 Malignant neoplasm of Thyroid Gland	C37.3, C73-C75	C73 Thyroid Gland, C75 Other Endocrine Glands and related structures.		
C74	C74 Malignant neoplasm of Adrenal Gland	C37.3, C73-C76	C34 Bronchus and Lung, C50 Breast, C74 Adrenal Gland, C75 Other Endocrine Glands and related structures.		
C75	C75 Malignant neoplasm of Other Endocrine Glands and related structures.	C37.3, C73-C77	C37.9 Thymus, C73 Thyroid Gland, C74 Adrenal Gland, C75 Other Endocrine Glands and related structures.		
C76-C80	Ill defined, Secondary and Unspecified Sites				
C76	C76 Malignant neoplasm of other and ill-defined sites	Any code			
C77	C77 Secondary and unspecified malignant neoplasm of lymph nodes	Any code			
C78	C78 Secondary malignant neoplasm of respiratory and digestive organs	C15-C39	C15-C26 Digestive Organs, C30-C39 Respiratory System and Intrathoracic Organs		
C79	C79 Secondary malignant neoplasm of other sites	not (C15-C39)	C15-C26 Digestive Organs, C30-C39 Respiratory System and Intrathoracic Organs		
C80	C80 Malignant neoplasm without specification of site	Any code			

Appendix C

C81-C96	C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue		Lymphoid, Haematopoietic and Related Tissue		
C81	C81 Hodgkin's disease			9590-9768	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases
C82	C82 Follicular [nodular] non-Hodgkin's lymphoma			9590-9768, 9823	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases, 9823 B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
C83	C83 Diffuse non-Hodgkin's lymphoma			9590-9768, 9823, 9827	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases, 9823 B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma and 9827 Adult T-cell leukemia/lymphoma
C84	C84 Peripheral and cutaneous T-cell lymphomas			9590-9768, 9827	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases, 9827 Adult T-cell leukemia/lymphoma
C85	C85 Other and unspecified types of non-Hodgkin's lymphoma			9590-9768, 9823, 9827	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases, 9823 B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma and 9827 Adult T-cell leukemia/lymphoma
C88	C88 Malignant immunoproliferative diseases			9590-9768, 9823, 9827	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases, 9823 B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma and 9827 Adult T-cell leukemia/lymphoma
C90	C90 Multiple myeloma and malignant plasma cell neoplasms			9590-9768	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases
C91	C91 Lymphoid leukemia	C42	C42 Hematopoietic and Reticuloendothelial systems	9800-9948	980-994 Leukemias
C92	C92 Myeloid leukemia			9800-9948	980-994 Leukemias
C93	C93 Monocytic leukemia			9800-9948	980-994 Leukemias
C94	C94 Other leukemia's of specified cell type			9800-9948	980-994 Leukemias
C95	C95 Leukemia of unspecified cell type			9800-9948	980-994 Leukemias
C96	C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue			9590-9989	959-972 Hodgkin and non-Hodgkin lymphomas, 973 Plasma cell tumours, 974 Mast cell tumours, 975 Neoplasms of histiocytes and accessory lymphoid cells, 976 Immunoproliferative diseases, 980-994 Leukemias, 995-996 Chronic myeloproliferative disorders (C42.1), 997 Other Hematologic disorders, 998 Myelodysplastic syndromes (C42.1)



Appendix C

<b>C97</b>	<b>C97 Malignant neoplasms of independent (primary) multiple sites</b>	<b>Independent Multiple Sites</b>			
C97	C97 Malignant neoplasms of independent (primary) multiple sites	not C44	C44 Skin	805-808, 809-811	805-808 Squamous cell neoplasms, 809-811 Basal cell neoplasms
<b>D00-D09</b>	<b>D00-D09 In situ neoplasms</b>		<b>In Situ</b>		
D00	D00 Carcinoma in situ of oral cavity, esophagus and stomach	C00-C16	C00-C14 Lip, Oral Cavity and Pharynx, C15 Esophagus, C16 Stomach		
D01	D01 Carcinoma in situ of other and unspecified digestive organs	C17-C26	C17 Stomach, C18 Colon, C19 Rectosigmoid Junction, C20 Rectum, C21 Anus and Anal Canal, C22 Liver and Intrahepatic Bile Ducts, C23 Gallbladder, C24 Other and unspec. Parts of biliary tract, C25 Pancreas, C26 Other and ill-defined digestive organs		
D02	D02 Carcinoma in situ of middle ear and respiratory system	C30-C39	C30 Nasal cavity and middle ear, C31 Accessory sinus, C32 Larynx, C33 Trachea, C34 Bronchus and lung, C37 Thymus, C38 Heart, Mediastinum and Pleura, C39 Other and ill-defined sites within respiratory system and intrathoracic organs		
D03	D03 Melanoma in situ	C44	C44 Skin	8720-8790	872-879 Nevi and Melanomas
D04	D04 Carcinoma in situ of skin	C44	C44 Skin	<b>not</b> (8720-8790)	
D05	D05 Carcinoma in situ of breast	C50	C50 Breast		
D06	D06 Carcinoma in situ of cervix uteri	C53	C53 Cervix Uteri		
D07	D07 Carcinoma in situ of other and unspecified genital organs	C51-C63	C51 Vulva, C52 Vagina, C53 Cervix Uteri, C54 Corpus Uteri, C55 Uterus, NOS, C56 Ovary, C57 Other and Unspec Female Genital Organs, C58 Placenta, C60 Penis, C61 Prostate Gland, C62 Testis, C63 Other and Unspec. Male Genital Organs		
D09	D09 Carcinoma in situ of other and unspecified sites	C64-C80	C64 Kidney, C65 Renal Pelvis, C66 Ureter, C67 Bladder, C68 Other and Unspec. Urinary Organs, C69 Eye and Adnexa, C70 Meninges, C71 Brain, C72 Spinal Cord, cranial nerves and other parts of CNS, C73 Thyroid Gland, C74 Adrenal Gland, C75 Other endocrine glands and related structures, C76 Other and ill-defined sites, C77 Lymph nodes, C80 Unknown Primary Site		
<b>D10-D36</b>	<b>Benign Neoplasms</b>		<b>Benign Neoplasms</b>		
D33	Benign neoplasm of brain and other parts of CNS	C71 (brain)	C71 Brain		